Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

I disagree. Brilacidin phase III in Oral Mucositis (OM) is further ahead than IBD, Ulcerative Colitis (UC). OM is likely our best chance to move forward in a timely manner if the covid trial doesn't meet endpoints. I have no idea why the decision was made to reformulate UC, but, it's not the only hope to move forward.

You may have missed that the UC reformulation decision had been listed in the 10K filed on 9.27.21 pg 12 https://www.sec.gov/Archives/edgar/data/1355250/000147793221006717/ipix_10k.htm

IBD, Ulcerative Colitis (UC) — Brilacidin is also being developed as a treatment in more extensive forms of IBD.

Development of a delayed release oral formulation has been in progress, with development work expanding into immediate release formulations due to unexpected findings encountered. Such findings appear due to the inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release. An immediate release, multi-particulate capsule formulation has been developed and a ‘research and development’ batch has progressed to stability testing at the manufacturing vendor. Further work is ongoing, in preparation for manufacture of clinical trial supplies.

Drug has already been ordered for a phase III OM trial which appears to be targeted for first part of 2022.

From 10K filed 9.27.21 pg 36 https://www.sec.gov/Archives/edgar/data/1355250/000147793221006717/ipix_10k.htm

We have ordered Brilacidin API (active pharmaceutical ingredient) for delivery in January 2022, for use in our planned oral mucositis Phase 3 clinical study. There is no assurance the order will be manufactured or received timely. We have encountered prior delays and cost overruns in ordering the production of Brilacidin API.

From company website you can see that Brilacidin OM is furthest along and in line with the 10K filing info above. http://www.ipharminc.com/stages-of-development



From 10Q filed 11.9.21 pg 28 you can also see Brilacidin OM is further along than Brilacidin UC. https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793221007937/ipix_10q.htm
















Message in reply to: BOLDED
Is anyone paying attn??? This is a CRITICAL find from the 10Q. The time and cash spent working on the long release B for UC- you all remember that, right?-may not be working out. All that chatter and effort with the delivery system and the drug availability-out the window? Buried in a 10 Q?

It will not be the end of the world if B beats C- and the data are conclusive.

HOWEVER, folks, this was the best hope for this company until 18 months ago when the moonshot for COVID took over.

UC was the last best chance for IP.

And now we are told that the delaYED RELEase tanked???
"Unexpected findings encountered"????

That is all we are told.

This is a big big problem for the company. It means there nay be nothing left to see here if the trial data fail.